Trastuzumab and breast cancer.
Rudlowski
C
C
Rath
W
W
Becker
A J
AJ
Wiestler
O D
OD
Buttner
R
R
D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D061067:Antibodies, Monoclonal, Humanized; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D001859:Bone Neoplasms / Q000188:drug therapy / Q000556:secondary; D018567:Breast Neoplasms, Male / Q000188:drug therapy / Q000473:pathology* / Q000601:surgery; D004164:Diphosphonates / Q000627:therapeutic use; D006801:Humans; D008175:Lung Neoplasms / Q000188:drug therapy* / Q000556:secondary*; D008297:Male; D008875:Middle Aged; D017239:Paclitaxel / Q000627:therapeutic use; D000077268:Pamidronate; D018719:Erb-b2 Receptor Tyrosine Kinases / Q000032:analysis* / Q000276:immunology; D000068878:Trastuzumab
D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D004164:Diphosphonates; D017239:Paclitaxel; D000077268:Pamidronate; D018719:Erb-b2 Receptor Tyrosine Kinases; D000068878:Trastuzumab